Search - tctmd.com

Displaying 1 - 12 of 12

Sort: Relevancy | Date

News Daily News

BP Reduction With Renal Denervation Still Evident a Decade On

Michael O'Riordan

January 31, 2023

News Conference News AHA 2022

SPYRAL HTN-ON MED Trial of Renal Denervation Misses Primary Endpoint

Todd Neale

November 09, 2022

News Conference News TCT 2022

RADIANCE II Confirms Ultrasound-Based Renal Denervation Lowers BP

Todd Neale

September 18, 2022

News Daily News

VERTIS CV: Ertugliflozin Meets Noninferiority Endpoint but Misses Other Marks

Michael O'Riordan

September 24, 2020

News Daily News

Longer Patency, Fewer Repeat Procedures With Paclitaxel DCBs in Dialysis Patients

L.A. McKeown

August 21, 2020

News Conference News CRT 2020

AKI After TAVR Is Decreasing, but More Efforts Needed to Prevent Stage 3

L.A. McKeown

February 27, 2020

News Daily News

‘People Are Pretty Optimistic’ as Renal Denervation’s Comeback Continues

Todd Neale

June 24, 2019

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for May 2019

Caitlin E. Cox

May 31, 2019

News Conference News ACC 2019

Renal Denervation May Lower Treatment Burden, as Well as Blood Pressure: RADIANCE-HTN SOLO

Michael O'Riordan

April 01, 2019

News Industry News

Boehringer Ingelheim and Lilly announce an academic collaboration with University of Oxford to investigate the effects of Jardiance® in adults with chronic kidney disease

April 26, 2018

News Conference News ACC 2014

Renal Denervation Fails to Meet Efficacy Endpoints Compared with Placebo Procedure

Yael L. Maxwell

March 29, 2014

News Daily News

Renal Denervation: Treatment for Hypertension Captures Interventional Spotlight

June 05, 2012

Advertisement

BP Reduction With Renal Denervation Still Evident a Decade On

SPYRAL HTN-ON MED Trial of Renal Denervation Misses Primary Endpoint

RADIANCE II Confirms Ultrasound-Based Renal Denervation Lowers BP

VERTIS CV: Ertugliflozin Meets Noninferiority Endpoint but Misses Other Marks

Longer Patency, Fewer Repeat Procedures With Paclitaxel DCBs in Dialysis Patients

AKI After TAVR Is Decreasing, but More Efforts Needed to Prevent Stage 3

‘People Are Pretty Optimistic’ as Renal Denervation’s Comeback Continues

TCTMD’s Top 10 Most Popular Stories for May 2019

Renal Denervation May Lower Treatment Burden, as Well as Blood Pressure: RADIANCE-HTN SOLO

Boehringer Ingelheim and Lilly announce an academic collaboration with University of Oxford to investigate the effects of Jardiance® in adults with chronic kidney disease

Renal Denervation Fails to Meet Efficacy Endpoints Compared with Placebo Procedure

Renal Denervation: Treatment for Hypertension Captures Interventional Spotlight

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content